EIDD-2801 has shown significant potential in antiviral applications, particularly in the treatment of RNA virus infections. It has been studied extensively for its efficacy against SARS-CoV-2, the virus responsible for COVID-19, where it acts as a broad-spectrum antiviral by introducing errors into the viral RNA during replication, thereby inhibiting its ability to spread. Beyond COVID-19, it has demonstrated activity against other RNA viruses such as influenza, Ebola, and respiratory syncytial virus (RSV), making it a promising candidate for addressing future viral outbreaks. Its oral bioavailability allows for convenient administration, which is advantageous in both clinical and outpatient settings. Research is ongoing to explore its potential in treating other viral infections and its role in combination therapies to enhance antiviral effects.